Biotech
Candid Therapeutics
Candid Therapeutics raises $370M Series A at $1.2B valuation
$370M
Total Raised
Series A
Latest Round
2023
Founded
70+
Employees
San Francisco, CA
1 min read
Quick Facts
Valuation
$1.2B
Latest Round Size
$370M
Latest Round Date
September 2024
Candid Therapeutics: Series A Funding Round
Candid Therapeutics has successfully raised $370M in Series A funding, reaching a valuation of $1.2B.
Company Overview
Developing novel therapeutics for autoimmune diseases
Funding Details
The Series A round was led by Venrock, with participation from Fairmount, TCGX.
Company Information
- Headquarters: San Francisco, CA
- Founded: 2023
- Employees: 70+
- Category: Biotech
Investment
Candid Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Venrock: Verified investor in Series A
- Fairmount: Verified investor in Series A
- TCGX: Verified investor in Series A
Key Investors
Venrock
Lead Investor
Verified investor in Series A
Fairmount
Investor
Verified investor in Series A
TCGX
Investor
Verified investor in Series A
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M